Skip to content

Study · Not a test of the peptide alone · 2026

80 results

Impact of GLP-1 receptor agonists on stroke, subarachnoid hemorrhage, and intracerebral hemorrhage: a propensity-matched multi-institutional cohort study.

Costa M, O'Leary S, Price AM, Young CC, Srinivasan VM, Kan P

Journal of neurosurgery3 Oct 2025Cited by 5 (Europe PMC)

PMID41043189 (opens in a new tab)DOI10.3171/2025.5.jns25786 (opens in a new tab)PepBankPUB-41043189
Publisher pagePubMedAsk about this study
Jump to 80 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study80

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone80

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to less rebleeding than control at 6 months (OR 0.73).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to less rebleeding than control at six months.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseaSAH rebleeding at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.73 ratio
    GLP-1 RA users vs matched controls, aSAH, 6 months, rebleeding
    p-value
    0.003 p
    GLP-1 RA users vs matched controls, aSAH, 6 months, rebleeding

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to less rebleeding than control at 6 months (OR 0.73).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to less rebleeding than control at six months.

    Peptide
    Liraglutide
    Outcome
    DecreaseaSAH rebleeding at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.73 ratio
    GLP-1 RA users vs matched controls, aSAH, 6 months, rebleeding
    p-value
    0.003 p
    GLP-1 RA users vs matched controls, aSAH, 6 months, rebleeding

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to less rebleeding than control at 6 months (OR 0.73).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to less rebleeding than control at six months.

    Peptide
    Semaglutide
    Outcome
    DecreaseaSAH rebleeding at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.73 ratio
    GLP-1 RA users vs matched controls, aSAH, 6 months, rebleeding
    p-value
    0.003 p
    GLP-1 RA users vs matched controls, aSAH, 6 months, rebleeding

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to less rebleeding than control at 6 months (OR 0.73).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to less rebleeding than control at six months.

    Peptide
    Tirzepatide
    Outcome
    DecreaseaSAH rebleeding at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.73 ratio
    GLP-1 RA users vs matched controls, aSAH, 6 months, rebleeding
    p-value
    0.003 p
    GLP-1 RA users vs matched controls, aSAH, 6 months, rebleeding

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  5. 05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to lower mortality than control at 6 months (OR 0.41).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to fewer deaths than control at six months.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseaSAH mortality at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    OR
    0.41 ratio
    GLP-1 RA users vs matched controls, aSAH, 6 months, mortality
    p-value
    < 0.001 p
    GLP-1 RA users vs matched controls, aSAH, 6 months, mortality

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  6. 06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to lower mortality than control at 6 months (OR 0.41).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to fewer deaths than control at six months.

    Peptide
    Liraglutide
    Outcome
    DecreaseaSAH mortality at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    OR
    0.41 ratio
    GLP-1 RA users vs matched controls, aSAH, 6 months, mortality
    p-value
    < 0.001 p
    GLP-1 RA users vs matched controls, aSAH, 6 months, mortality

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to lower mortality than control at 6 months (OR 0.41).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to fewer deaths than control at six months.

    Peptide
    Semaglutide
    Outcome
    DecreaseaSAH mortality at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    OR
    0.41 ratio
    GLP-1 RA users vs matched controls, aSAH, 6 months, mortality
    p-value
    < 0.001 p
    GLP-1 RA users vs matched controls, aSAH, 6 months, mortality

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 08HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to lower mortality than control at 6 months (OR 0.41).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to fewer deaths than control at six months.

    Peptide
    Tirzepatide
    Outcome
    DecreaseaSAH mortality at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    OR
    0.41 ratio
    GLP-1 RA users vs matched controls, aSAH, 6 months, mortality
    p-value
    < 0.001 p
    GLP-1 RA users vs matched controls, aSAH, 6 months, mortality

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  9. 09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to fewer cognitive deficits than control at 1 year (OR 0.63).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to fewer cognitive deficits than control at one year.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseaSAH cognitive deficits at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cognition and memory · Nervous system and cognition

    Measurements

    OR
    0.63 ratio
    GLP-1 RA users vs matched controls, aSAH, 1 year, cognitive deficits
    p-value
    0.034 p
    GLP-1 RA users vs matched controls, aSAH, 1 year, cognitive deficits

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  10. 10HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to fewer cognitive deficits than control at 1 year (OR 0.63).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to fewer cognitive deficits than control at one year.

    Peptide
    Liraglutide
    Outcome
    DecreaseaSAH cognitive deficits at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cognition and memory · Nervous system and cognition

    Measurements

    OR
    0.63 ratio
    GLP-1 RA users vs matched controls, aSAH, 1 year, cognitive deficits
    p-value
    0.034 p
    GLP-1 RA users vs matched controls, aSAH, 1 year, cognitive deficits

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  11. 11HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to fewer cognitive deficits than control at 1 year (OR 0.63).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to fewer cognitive deficits than control at one year.

    Peptide
    Semaglutide
    Outcome
    DecreaseaSAH cognitive deficits at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cognition and memory · Nervous system and cognition

    Measurements

    OR
    0.63 ratio
    GLP-1 RA users vs matched controls, aSAH, 1 year, cognitive deficits
    p-value
    0.034 p
    GLP-1 RA users vs matched controls, aSAH, 1 year, cognitive deficits

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  12. 12HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to fewer cognitive deficits than control at 1 year (OR 0.63).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to fewer cognitive deficits than control at one year.

    Peptide
    Tirzepatide
    Outcome
    DecreaseaSAH cognitive deficits at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cognition and memory · Nervous system and cognition

    Measurements

    OR
    0.63 ratio
    GLP-1 RA users vs matched controls, aSAH, 1 year, cognitive deficits
    p-value
    0.034 p
    GLP-1 RA users vs matched controls, aSAH, 1 year, cognitive deficits

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  13. 13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to lower mortality than control at 1 year (OR 0.39).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to fewer deaths than control at one year.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseaSAH mortality at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    OR
    0.39 ratio
    GLP-1 RA users vs matched controls, aSAH, 1 year, mortality
    p-value
    < 0.001 p
    GLP-1 RA users vs matched controls, aSAH, 1 year, mortality

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  14. 14HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to lower mortality than control at 1 year (OR 0.39).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to fewer deaths than control at one year.

    Peptide
    Liraglutide
    Outcome
    DecreaseaSAH mortality at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    OR
    0.39 ratio
    GLP-1 RA users vs matched controls, aSAH, 1 year, mortality
    p-value
    < 0.001 p
    GLP-1 RA users vs matched controls, aSAH, 1 year, mortality

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  15. 15HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to lower mortality than control at 1 year (OR 0.39).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to fewer deaths than control at one year.

    Peptide
    Semaglutide
    Outcome
    DecreaseaSAH mortality at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    OR
    0.39 ratio
    GLP-1 RA users vs matched controls, aSAH, 1 year, mortality
    p-value
    < 0.001 p
    GLP-1 RA users vs matched controls, aSAH, 1 year, mortality

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  16. 16HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In aSAH patients, pooled GLP-1 drug use was linked to lower mortality than control at 1 year (OR 0.39).

    In plain wordsIn aSAH patients, pooled GLP-1 drug use was linked to fewer deaths than control at one year.

    Peptide
    Tirzepatide
    Outcome
    DecreaseaSAH mortality at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    OR
    0.39 ratio
    GLP-1 RA users vs matched controls, aSAH, 1 year, mortality
    p-value
    < 0.001 p
    GLP-1 RA users vs matched controls, aSAH, 1 year, mortality

    Source sentences

    Summary
    For aSAH patients, GLP-1-RA use at 6 months reduced rebleeding (OR 0.73, p = 0.003) and mortality (OR 0.41, p < 0.001) and at 1 year lowered cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  17. 17HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at 6 months (OR 0.37).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at six months.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasesICH hydrocephalus at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.37 ratio
    GLP-1 RA users vs matched controls, sICH, 6 months, hydrocephalus
    p-value
    0.005 p
    GLP-1 RA users vs matched controls, sICH, 6 months, hydrocephalus

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  18. 18HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at 6 months (OR 0.37).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at six months.

    Peptide
    Liraglutide
    Outcome
    DecreasesICH hydrocephalus at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.37 ratio
    GLP-1 RA users vs matched controls, sICH, 6 months, hydrocephalus
    p-value
    0.005 p
    GLP-1 RA users vs matched controls, sICH, 6 months, hydrocephalus

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  19. 19HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at 6 months (OR 0.37).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at six months.

    Peptide
    Semaglutide
    Outcome
    DecreasesICH hydrocephalus at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.37 ratio
    GLP-1 RA users vs matched controls, sICH, 6 months, hydrocephalus
    p-value
    0.005 p
    GLP-1 RA users vs matched controls, sICH, 6 months, hydrocephalus

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  20. 20HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at 6 months (OR 0.37).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at six months.

    Peptide
    Tirzepatide
    Outcome
    DecreasesICH hydrocephalus at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.37 ratio
    GLP-1 RA users vs matched controls, sICH, 6 months, hydrocephalus
    p-value
    0.005 p
    GLP-1 RA users vs matched controls, sICH, 6 months, hydrocephalus

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  21. 21HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at 6 months (OR 0.56).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at six months.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasesICH seizures at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.56 ratio
    GLP-1 RA users vs matched controls, sICH, 6 months, seizures
    p-value
    0.007 p
    GLP-1 RA users vs matched controls, sICH, 6 months, seizures

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  22. 22HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at 6 months (OR 0.56).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at six months.

    Peptide
    Liraglutide
    Outcome
    DecreasesICH seizures at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.56 ratio
    GLP-1 RA users vs matched controls, sICH, 6 months, seizures
    p-value
    0.007 p
    GLP-1 RA users vs matched controls, sICH, 6 months, seizures

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  23. 23HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at 6 months (OR 0.56).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at six months.

    Peptide
    Semaglutide
    Outcome
    DecreasesICH seizures at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.56 ratio
    GLP-1 RA users vs matched controls, sICH, 6 months, seizures
    p-value
    0.007 p
    GLP-1 RA users vs matched controls, sICH, 6 months, seizures

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  24. 24HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at 6 months (OR 0.56).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at six months.

    Peptide
    Tirzepatide
    Outcome
    DecreasesICH seizures at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.56 ratio
    GLP-1 RA users vs matched controls, sICH, 6 months, seizures
    p-value
    0.007 p
    GLP-1 RA users vs matched controls, sICH, 6 months, seizures

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  25. 25HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at 1 year (OR 0.38).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at one year.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasesICH hydrocephalus at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.38 ratio
    GLP-1 RA users vs matched controls, sICH, 1 year, hydrocephalus
    p-value
    0.007 p
    GLP-1 RA users vs matched controls, sICH, 1 year, hydrocephalus

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  26. 26HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at 1 year (OR 0.38).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at one year.

    Peptide
    Liraglutide
    Outcome
    DecreasesICH hydrocephalus at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.38 ratio
    GLP-1 RA users vs matched controls, sICH, 1 year, hydrocephalus
    p-value
    0.007 p
    GLP-1 RA users vs matched controls, sICH, 1 year, hydrocephalus

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  27. 27HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at 1 year (OR 0.38).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at one year.

    Peptide
    Semaglutide
    Outcome
    DecreasesICH hydrocephalus at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.38 ratio
    GLP-1 RA users vs matched controls, sICH, 1 year, hydrocephalus
    p-value
    0.007 p
    GLP-1 RA users vs matched controls, sICH, 1 year, hydrocephalus

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  28. 28HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at 1 year (OR 0.38).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at one year.

    Peptide
    Tirzepatide
    Outcome
    DecreasesICH hydrocephalus at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    OR
    0.38 ratio
    GLP-1 RA users vs matched controls, sICH, 1 year, hydrocephalus
    p-value
    0.007 p
    GLP-1 RA users vs matched controls, sICH, 1 year, hydrocephalus

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  29. 29HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at 1 year (OR 0.63).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at one year.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasesICH seizures at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.63 ratio
    sICH patients, GLP-1-RA use vs matched controls, 1 year

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  30. 30HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at 1 year (OR 0.63).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at one year.

    Peptide
    Liraglutide
    Outcome
    DecreasesICH seizures at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.63 ratio
    sICH patients, GLP-1-RA use vs matched controls, 1 year

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  31. 31HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at 1 year (OR 0.63).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at one year.

    Peptide
    Semaglutide
    Outcome
    DecreasesICH seizures at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.63 ratio
    sICH patients, GLP-1-RA use vs matched controls, 1 year

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  32. 32HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at 1 year (OR 0.63).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to fewer seizures than control at one year.

    Peptide
    Tirzepatide
    Outcome
    DecreasesICH seizures at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.63 ratio
    sICH patients, GLP-1-RA use vs matched controls, 1 year

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  33. 33HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to lower mortality than control at both follow-ups (OR 0.45-0.40).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to fewer deaths than control at both follow-ups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasesICH mortality at six and twelve months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    odds ratio
    0.4 to 0.45 ratio
    sICH patients, GLP-1-RA use vs matched controls, 6 and 12 months

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  34. 34HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to lower mortality than control at both follow-ups (OR 0.45-0.40).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to fewer deaths than control at both follow-ups.

    Peptide
    Liraglutide
    Outcome
    DecreasesICH mortality at six and twelve months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    odds ratio
    0.4 to 0.45 ratio
    sICH patients, GLP-1-RA use vs matched controls, 6 and 12 months

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  35. 35HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to lower mortality than control at both follow-ups (OR 0.45-0.40).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to fewer deaths than control at both follow-ups.

    Peptide
    Semaglutide
    Outcome
    DecreasesICH mortality at six and twelve months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    odds ratio
    0.4 to 0.45 ratio
    sICH patients, GLP-1-RA use vs matched controls, 6 and 12 months

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  36. 36HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to lower mortality than control at both follow-ups (OR 0.45-0.40).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to fewer deaths than control at both follow-ups.

    Peptide
    Tirzepatide
    Outcome
    DecreasesICH mortality at six and twelve months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    odds ratio
    0.4 to 0.45 ratio
    sICH patients, GLP-1-RA use vs matched controls, 6 and 12 months

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  37. 37HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to less rebleeding than control at both follow-ups (OR 0.70-0.69).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to less rebleeding than control at both follow-ups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasesICH rebleeding at six and twelve months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.69 to 0.7 ratio
    sICH patients, GLP-1-RA use vs matched controls, 6 and 12 months

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  38. 38HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to less rebleeding than control at both follow-ups (OR 0.70-0.69).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to less rebleeding than control at both follow-ups.

    Peptide
    Liraglutide
    Outcome
    DecreasesICH rebleeding at six and twelve months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.69 to 0.7 ratio
    sICH patients, GLP-1-RA use vs matched controls, 6 and 12 months

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  39. 39HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to less rebleeding than control at both follow-ups (OR 0.70-0.69).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to less rebleeding than control at both follow-ups.

    Peptide
    Semaglutide
    Outcome
    DecreasesICH rebleeding at six and twelve months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.69 to 0.7 ratio
    sICH patients, GLP-1-RA use vs matched controls, 6 and 12 months

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  40. 40HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In sICH patients, pooled GLP-1 drug use was linked to less rebleeding than control at both follow-ups (OR 0.70-0.69).

    In plain wordsIn sICH patients, pooled GLP-1 drug use was linked to less rebleeding than control at both follow-ups.

    Peptide
    Tirzepatide
    Outcome
    DecreasesICH rebleeding at six and twelve months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.69 to 0.7 ratio
    sICH patients, GLP-1-RA use vs matched controls, 6 and 12 months

    Source sentences

    Summary
    In sICH patients, GLP-1-RAs decreased hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at 6 months, with persistent benefits at 1 year (hydrocephalus, OR 0.38, p = 0.007; seizures, OR 0.63, p = 0.018), alongside lower mortality (OR 0.45-0.40, both p < 0.001) and rebleeding (OR 0.…
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  41. 41HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to lower mortality than control at 6 months (OR 0.27).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to fewer deaths than control at six months.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAIS mortality at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    odds ratio
    0.27 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  42. 42HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to lower mortality than control at 6 months (OR 0.27).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to fewer deaths than control at six months.

    Peptide
    Liraglutide
    Outcome
    DecreaseAIS mortality at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    odds ratio
    0.27 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  43. 43HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to lower mortality than control at 6 months (OR 0.27).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to fewer deaths than control at six months.

    Peptide
    Semaglutide
    Outcome
    DecreaseAIS mortality at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    odds ratio
    0.27 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  44. 44HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to lower mortality than control at 6 months (OR 0.27).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to fewer deaths than control at six months.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAIS mortality at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    odds ratio
    0.27 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  45. 45HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to lower mortality than control at 1 year (OR 0.44).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to fewer deaths than control at one year.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAIS mortality at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    odds ratio
    0.44 ratio
    AIS patients, GLP-1-RA use vs matched controls, 1 year

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  46. 46HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to lower mortality than control at 1 year (OR 0.44).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to fewer deaths than control at one year.

    Peptide
    Liraglutide
    Outcome
    DecreaseAIS mortality at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    odds ratio
    0.44 ratio
    AIS patients, GLP-1-RA use vs matched controls, 1 year

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  47. 47HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to lower mortality than control at 1 year (OR 0.44).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to fewer deaths than control at one year.

    Peptide
    Semaglutide
    Outcome
    DecreaseAIS mortality at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    odds ratio
    0.44 ratio
    AIS patients, GLP-1-RA use vs matched controls, 1 year

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  48. 48HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to lower mortality than control at 1 year (OR 0.44).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to fewer deaths than control at one year.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAIS mortality at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Mortality · Nervous system and cognition

    Measurements

    odds ratio
    0.44 ratio
    AIS patients, GLP-1-RA use vs matched controls, 1 year

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  49. 49HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to less recurrence than control at 6 months (OR 0.60).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to less recurrence than control at six months.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAIS recurrence at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.6 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  50. 50HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to less recurrence than control at 6 months (OR 0.60).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to less recurrence than control at six months.

    Peptide
    Liraglutide
    Outcome
    DecreaseAIS recurrence at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.6 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  51. 51HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to less recurrence than control at 6 months (OR 0.60).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to less recurrence than control at six months.

    Peptide
    Semaglutide
    Outcome
    DecreaseAIS recurrence at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.6 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  52. 52HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to less recurrence than control at 6 months (OR 0.60).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to less recurrence than control at six months.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAIS recurrence at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.6 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  53. 53HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at 6 months (OR 0.32).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at six months.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAIS hydrocephalus at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.32 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  54. 54HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at 6 months (OR 0.32).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at six months.

    Peptide
    Liraglutide
    Outcome
    DecreaseAIS hydrocephalus at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.32 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  55. 55HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at 6 months (OR 0.32).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at six months.

    Peptide
    Semaglutide
    Outcome
    DecreaseAIS hydrocephalus at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.32 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  56. 56HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at 6 months (OR 0.32).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to less hydrocephalus than control at six months.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAIS hydrocephalus at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.32 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  57. 57HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to fewer seizures than control at 6 months (OR 0.43).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to fewer seizures than control at six months.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAIS seizures at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.43 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  58. 58HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to fewer seizures than control at 6 months (OR 0.43).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to fewer seizures than control at six months.

    Peptide
    Liraglutide
    Outcome
    DecreaseAIS seizures at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.43 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  59. 59HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to fewer seizures than control at 6 months (OR 0.43).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to fewer seizures than control at six months.

    Peptide
    Semaglutide
    Outcome
    DecreaseAIS seizures at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.43 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  60. 60HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In AIS patients, pooled GLP-1 drug use was linked to fewer seizures than control at 6 months (OR 0.43).

    In plain wordsIn AIS patients, pooled GLP-1 drug use was linked to fewer seizures than control at six months.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAIS seizures at six months
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    odds ratio
    0.43 ratio
    AIS patients, GLP-1-RA use vs matched controls, 6 months

    Source sentences

    Summary
    In AIS patients, mortality fell at 6 months (OR 0.27, p < 0.001) and 1 year (OR 0.44, p < 0.001), with reduced recurrence (OR 0.60, p < 0.001) and lower hydrocephalus (OR 0.32, p < 0.001) and seizure (OR 0.43, p < 0.001) rates at 6 months.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  61. 61HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In the cohort, pooled GLP-1 drug use was linked to lower SAH incidence than control at 1 year (OR 0.64).

    In plain wordsPooled GLP-1 drug use was linked to lower SAH incidence than control at one year.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseSAH incidence at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    odds ratio
    0.64 ratio
    GLP-1-RA users vs matched controls, 1 year

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  62. 62HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In the cohort, pooled GLP-1 drug use was linked to lower SAH incidence than control at 1 year (OR 0.64).

    In plain wordsPooled GLP-1 drug use was linked to lower SAH incidence than control at one year.

    Peptide
    Liraglutide
    Outcome
    DecreaseSAH incidence at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    odds ratio
    0.64 ratio
    GLP-1-RA users vs matched controls, 1 year

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  63. 63HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In the cohort, pooled GLP-1 drug use was linked to lower SAH incidence than control at 1 year (OR 0.64).

    In plain wordsPooled GLP-1 drug use was linked to lower SAH incidence than control at one year.

    Peptide
    Semaglutide
    Outcome
    DecreaseSAH incidence at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    odds ratio
    0.64 ratio
    GLP-1-RA users vs matched controls, 1 year

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  64. 64HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In the cohort, pooled GLP-1 drug use was linked to lower SAH incidence than control at 1 year (OR 0.64).

    In plain wordsPooled GLP-1 drug use was linked to lower SAH incidence than control at one year.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSAH incidence at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    odds ratio
    0.64 ratio
    GLP-1-RA users vs matched controls, 1 year

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  65. 65HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In the cohort, pooled GLP-1 drug use was linked to lower ICH incidence than control at 1 year (OR 0.62).

    In plain wordsPooled GLP-1 drug use was linked to lower ICH incidence than control at one year.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseICH incidence at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    odds ratio
    0.62 ratio
    GLP-1-RA users vs matched controls, 1 year

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  66. 66HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In the cohort, pooled GLP-1 drug use was linked to lower ICH incidence than control at 1 year (OR 0.62).

    In plain wordsPooled GLP-1 drug use was linked to lower ICH incidence than control at one year.

    Peptide
    Liraglutide
    Outcome
    DecreaseICH incidence at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    odds ratio
    0.62 ratio
    GLP-1-RA users vs matched controls, 1 year

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  67. 67HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In the cohort, pooled GLP-1 drug use was linked to lower ICH incidence than control at 1 year (OR 0.62).

    In plain wordsPooled GLP-1 drug use was linked to lower ICH incidence than control at one year.

    Peptide
    Semaglutide
    Outcome
    DecreaseICH incidence at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    odds ratio
    0.62 ratio
    GLP-1-RA users vs matched controls, 1 year

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  68. 68HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In the cohort, pooled GLP-1 drug use was linked to lower ICH incidence than control at 1 year (OR 0.62).

    In plain wordsPooled GLP-1 drug use was linked to lower ICH incidence than control at one year.

    Peptide
    Tirzepatide
    Outcome
    DecreaseICH incidence at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    odds ratio
    0.62 ratio
    GLP-1-RA users vs matched controls, 1 year

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  69. 69HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In the cohort, pooled GLP-1 drug use was linked to lower AIS incidence than control at 1 year (OR 0.82).

    In plain wordsPooled GLP-1 drug use was linked to lower AIS incidence than control at one year.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAIS incidence at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    Odds ratio
    0.82
    AIS incidence at 1 year, pooled GLP-1 receptor agonist users versus matched controls

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  70. 70HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In the cohort, pooled GLP-1 drug use was linked to lower AIS incidence than control at 1 year (OR 0.82).

    In plain wordsPooled GLP-1 drug use was linked to lower AIS incidence than control at one year.

    Peptide
    Liraglutide
    Outcome
    DecreaseAIS incidence at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    Odds ratio
    0.82
    AIS incidence at 1 year, pooled GLP-1 receptor agonist users versus matched controls

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  71. 71HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In the cohort, pooled GLP-1 drug use was linked to lower AIS incidence than control at 1 year (OR 0.82).

    In plain wordsPooled GLP-1 drug use was linked to lower AIS incidence than control at one year.

    Peptide
    Semaglutide
    Outcome
    DecreaseAIS incidence at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    Odds ratio
    0.82
    AIS incidence at 1 year, pooled GLP-1 receptor agonist users versus matched controls

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  72. 72HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In the cohort, pooled GLP-1 drug use was linked to lower AIS incidence than control at 1 year (OR 0.82).

    In plain wordsPooled GLP-1 drug use was linked to lower AIS incidence than control at one year.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAIS incidence at one year
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    Odds ratio
    0.82
    AIS incidence at 1 year, pooled GLP-1 receptor agonist users versus matched controls

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  73. 73HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In the cohort, lower stroke-subtype incidence with pooled GLP-1 drug use versus control persisted at 2 years (ORs 0.77-0.87).

    In plain wordsPooled GLP-1 drug use remained linked to lower stroke-subtype incidence than control at two years.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseStroke subtype incidence at two years
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    Odds ratio
    0.77 to 0.87
    stroke-type incidence at 2 years, pooled GLP-1 receptor agonist users versus matched controls

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  74. 74HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In the cohort, lower stroke-subtype incidence with pooled GLP-1 drug use versus control persisted at 2 years (ORs 0.77-0.87).

    In plain wordsPooled GLP-1 drug use remained linked to lower stroke-subtype incidence than control at two years.

    Peptide
    Liraglutide
    Outcome
    DecreaseStroke subtype incidence at two years
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    Odds ratio
    0.77 to 0.87
    stroke-type incidence at 2 years, pooled GLP-1 receptor agonist users versus matched controls

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  75. 75HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In the cohort, lower stroke-subtype incidence with pooled GLP-1 drug use versus control persisted at 2 years (ORs 0.77-0.87).

    In plain wordsPooled GLP-1 drug use remained linked to lower stroke-subtype incidence than control at two years.

    Peptide
    Semaglutide
    Outcome
    DecreaseStroke subtype incidence at two years
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    Odds ratio
    0.77 to 0.87
    stroke-type incidence at 2 years, pooled GLP-1 receptor agonist users versus matched controls

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  76. 76HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In the cohort, lower stroke-subtype incidence with pooled GLP-1 drug use versus control persisted at 2 years (ORs 0.77-0.87).

    In plain wordsPooled GLP-1 drug use remained linked to lower stroke-subtype incidence than control at two years.

    Peptide
    Tirzepatide
    Outcome
    DecreaseStroke subtype incidence at two years
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Cardiovascular events · Nervous system and cognition

    Measurements

    Odds ratio
    0.77 to 0.87
    stroke-type incidence at 2 years, pooled GLP-1 receptor agonist users versus matched controls

    Source sentences

    Summary
    At 1 year, GLP-1-RA users had lower incidence rates of SAH (OR 0.64, p = 0.001), ICH (OR 0.62, p < 0.001), and AIS (OR 0.82, p = 0.003), which were sustained at 2 years (ORs 0.77-0.87, all p < 0.05).
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  77. 77HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    In stroke cohorts, adverse events were similar between pooled GLP-1 drug users and matched controls.

    In plain wordsIn stroke cohorts, adverse events were similar between pooled GLP-1 drug users and matched controls.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeAdverse events
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Adverse events were similar.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  78. 78HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In stroke cohorts, adverse events were similar between pooled GLP-1 drug users and matched controls.

    In plain wordsIn stroke cohorts, adverse events were similar between pooled GLP-1 drug users and matched controls.

    Peptide
    Liraglutide
    Outcome
    No significant changeAdverse events
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Adverse events were similar.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  79. 79HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In stroke cohorts, adverse events were similar between pooled GLP-1 drug users and matched controls.

    In plain wordsIn stroke cohorts, adverse events were similar between pooled GLP-1 drug users and matched controls.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse events
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Adverse events were similar.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  80. 80HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    In stroke cohorts, adverse events were similar between pooled GLP-1 drug users and matched controls.

    In plain wordsIn stroke cohorts, adverse events were similar between pooled GLP-1 drug users and matched controls.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAdverse events
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Adverse events were similar.
    3 context sentences
    Summary · context
    This retrospective study leveraged TriNetX data (2014-2024) to identify patients with aSAH, sICH, or AIS.
    Summary · context
    Individuals receiving exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, or tirzepatide within 8 weeks of diagnosis were propensity matched to controls.
    Summary · context
    Outcomes (e.g., mortality, rebleeding/recurrence, seizures, hydrocephalus) were assessed at 6 and 12 months; the incidence rates of stroke types were examined at 1 and 2 years.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 6Current

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  2. Version 5

    22 Oct 2026, 02:25 UTC

    Study results updated

  3. Versions 2 to 4

    21 Oct 2026, 18:59 UTC

    The same notice was added 3 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.